Relevant bibliographies by topics / Tenofovir Disoproxil Fumarate (TDF)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Tenofovir Disoproxil Fumarate (TDF)'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Tenofovir Disoproxil Fumarate (TDF).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Tenofovir Disoproxil Fumarate (TDF)"

1

Ng, Hanna H., Howard Stock, Linda Rausch, et al. "Tenofovir Disoproxil Fumarate." International Journal of Toxicology 34, no. 1 (2015): 4–10. http://dx.doi.org/10.1177/1091581814565669.

Full text
Abstract:
Tenofovir disoproxil fumarate (TDF) is a prodrug of tenofovir that exhibits activity against HIV and hepatitis B. The goals of this study were to evaluate the molecular mechanism of TDF-induced toxicity in mice after 13 weeks of daily oral administration (50-1000 mg/kg) by correlating transcriptional changes with plasma drug levels and traditional toxicology end points. Plasma levels and systemic exposure of tenofovir increased less than dose proportionally and were similar on days 1 and 91. No overt toxicity was observed following the completion of TDF administration. The kidneys of TDF-treat
APA, Harvard, Vancouver, ISO, and other styles
2

Dewi, Putu Itta Sandi Lesmana, Kadek Mercu Narapati Pamungkas, and I. Ketut Mariadi. "Renal Safety of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B Patients: An Evidence-based Case Report." Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy 25, no. 2 (2024): 187–93. https://doi.org/10.24871/2522024368.

Full text
Abstract:
ABSTRACTBackground: Treatment modalities for chronic hepatitis B infection (CHB) are interferon and antiviral. The most commonly used antiviral is tenofovir disoproxil fumarate (TDF), however it is known to have nephrotoxicity. Recently, a new antiviral tenofovir alafenamide (TAF) has been developed, which also inhibits hepatitis B virus (HBV). This study aimed to compare the renal safety of TAF and TDF.Method: Literature searching was conducted in PubMed/Medline and Cochrane databases, with modified keywords as “chronic hepatitis B”, “tenofovir alafenamide”, “tenofovir disoproxil fumarate”, “
APA, Harvard, Vancouver, ISO, and other styles
3

Dickson, Sean, and Katelyn James. "Trends in HIV preexposure prophylaxis utilization and spending among individuals with commercial insurance." AIDS 38, no. 4 (2024): 610–12. http://dx.doi.org/10.1097/qad.0000000000003809.

Full text
Abstract:
In a cross-sectional analysis of HIV preexposure prophylaxis (PrEP) utilization by commercially insured patients from 2019 to 2021, most prescriptions were for branded formulations of PrEP despite the availability of a generic version. Accounting for the modest relative clinical benefit of branded TAF/FTC (tenofovir alafenamide fumarate/emtricitabine) PrEP over generic TDF/FTC (tenofovir disoproxil fumarate/emtricitabine) PrEP, use of generic TDF/FTC PrEP would have reduced commercial insurers’ spending by 33%.
APA, Harvard, Vancouver, ISO, and other styles
4

Lee, William A., and Andrew K. Cheng. "Tenofovir alafenamide fumarate." Antiviral Therapy 27, no. 1 (2022): 135965352110676. http://dx.doi.org/10.1177/13596535211067600.

Full text
Abstract:
Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that replicate HIV. Due to its selectivity for these tissues, lower total doses of TAF can be administered relative to tenofovir disoproxil fumarate (TDF) which results in improved bone and renal biomarkers. Tenofovir alafenamide fumarate has become the “backbone” of multiple combination products for the treatment of HIV, combined with emtricitabine for PreP and as a
APA, Harvard, Vancouver, ISO, and other styles
5

Wassner, Chanie, Nicole Bradley, and Yuman Lee. "A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide." Journal of the International Association of Providers of AIDS Care (JIAPAC) 19 (January 1, 2020): 232595822091923. http://dx.doi.org/10.1177/2325958220919231.

Full text
Abstract:
HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to control viral replication and prevent complications. Some of the older agents are notorious for many side effects, making patient compliance difficult, which is critical to preventing HIV resistance. Tenofovir is one of the newer, more tolerable, nucleotide reverse transcriptase inhibitors on the market; is a mainstay of many antiretroviral thera
APA, Harvard, Vancouver, ISO, and other styles
6

Brooks, Kristina M., Jose R. Castillo-Mancilla, Joshua Blum, et al. "Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir." Journal of Antimicrobial Chemotherapy 74, no. 8 (2019): 2360–64. http://dx.doi.org/10.1093/jac/dkz184.

Full text
Abstract:
AbstractBackgroundIntracellular tenofovir diphosphate concentrations are markedly increased in HIV/HCV coinfected individuals receiving tenofovir disoproxil fumarate (TDF) with sofosbuvir-containing treatment. Sofosbuvir may inhibit the hydrolysis of TDF to tenofovir, resulting in increased concentrations of the disoproxil or monoester forms, which may augment cell loading. We sought to quantify tenofovir disoproxil and monoester concentrations in individuals receiving TDF with and without ledipasvir/sofosbuvir.MethodsHIV/HCV coinfected participants receiving TDF-based therapy were sampled pre
APA, Harvard, Vancouver, ISO, and other styles
7

Huynh, Tung, Delana MyAn Bui, Tina Xiwen Zhou, and Ke-Qin Hu. "Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years." World Journal of Hepatology 16, no. 7 (2024): 1009–17. http://dx.doi.org/10.4254/wjh.v16.i7.1009.

Full text
Abstract:
BACKGROUND Both tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are the first-line treatments for chronic hepatitis B (CHB). We have showed switching from TDF to TAF for 96 weeks resulted in further alanine aminotransferase (ALT) improvement, but data remain lacking on the long-term benefits of TDF switching to TAF on hepatic fibrosis. AIM To assess the benefits of TDF switching to TAF for 3 years on ALT, aspartate aminotransferase (AST), and hepatic fibrosis improvement in patients with CHB. METHODS A single center retrospective study on 53 patients with CHB who were initi
APA, Harvard, Vancouver, ISO, and other styles
8

De Clercq, Erik. "Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)." Biochemical Pharmacology 119 (November 2016): 1–7. http://dx.doi.org/10.1016/j.bcp.2016.04.015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Agbaji, Oche O., Isaac O. Abah, Augustine O. Ebonyi, et al. "Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults." Journal of the International Association of Providers of AIDS Care (JIAPAC) 18 (January 1, 2019): 232595821882196. http://dx.doi.org/10.1177/2325958218821963.

Full text
Abstract:
Objectives and Method: There are growing concerns of tenofovir disoproxil fumarate (TDF)–associated renal toxicity. We evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015. Multivariate logistic regression was used to identify predictors of renal impairment at different time over 144 weeks of antiretroviral therapy (ART). Results: Data of 4897 patients, median age 42 years (interquartile range: 36-49), and 61% females were analyzed. The prevalence of renal impairment increased from 10% at week 24 to 45% at 144 weeks in T
APA, Harvard, Vancouver, ISO, and other styles
10

Liu, Rui, Jin Qiao, Lin Zhang, and Zhihua Dou. "Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B." Medicine 103, no. 20 (2024): e37953. http://dx.doi.org/10.1097/md.0000000000037953.

Full text
Abstract:
To explore the therapeutic effectiveness of tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) on the treatment for chronic hepatitis B (CHB). Retrospectively analyzing 241 cases of chronic hepatitis B patients admitted to our hospital from January 2020 to December 2021, they were divided into a TAF group of 180 cases and a TDF group of 61 cases. The liver function, serum virus markers, clinical efficacy, adverse reactions and cost-effectiveness ratio (CER) analysis of 2 groups were compared. Two groups of patients had no statistically significant difference in the levels of a
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Tenofovir Disoproxil Fumarate (TDF)"

1

Moraes, Filho Aroldo Vieira de. "Estudo da toxicidade genética de efavirenz (EFV) e fumarato de tenofovir desoproxila (TDF) em células somáticas de drosophila melanogaster." Universidade Federal de Goiás, 2013. http://repositorio.bc.ufg.br/tede/handle/tede/7396.

Full text
Abstract:
Submitted by JÚLIO HEBER SILVA (julioheber@yahoo.com.br) on 2017-05-31T18:35:47Z No. of bitstreams: 2 Dissertação - Aroldo Vieira de Moraes Filho - 2013.pdf: 777889 bytes, checksum: ff3a609fe7af52fcc55701fe96a8d450 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)<br>Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-06-01T11:20:13Z (GMT) No. of bitstreams: 2 Dissertação - Aroldo Vieira de Moraes Filho - 2013.pdf: 777889 bytes, checksum: ff3a609fe7af52fcc55701fe96a8d450 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf842
APA, Harvard, Vancouver, ISO, and other styles
2

Gomez, Camacho Mario Alberto [Verfasser], and Johannes [Akademischer Betreuer] Bogner. "Eine retrospektive Analyse der Gewichtsveränderungen bei HIV-positiven Patienten, die von einer Tenofovir-Disoproxil-Fumarat (TDF) zu einer Tenofovir-Alafenamid-Fumarat (TAF)-haltigen Therapie in einer deutschen Universitätsklinik im Zeitraum 2015-2017 wechseln / Mario Alberto Gomez Camacho ; Betreuer: Johannes Bogner." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2021. http://d-nb.info/1238518761/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dube, Tawanda. "Formulation, development and assessment of tenofovir disoproxil fumarate-loaded pellets." Thesis, Rhodes University, 2015. http://hdl.handle.net/10962/54690.

Full text
Abstract:
Tenofovir disoproxil fumarate (TDF) is a novel nucleotide analog reverse transcriptase inhibitor that is recommended by the WHO for use in first line treatment of HIV infections. Due to the high dose of TDF for anti-retroviral treatment the formulation of a pellet dosage form may improve patient adherence by incorporation of a large dose in a relatively small dosage form. TDF is currently only available in tablet form. A simple, sensitive, selective, rapid, accurate, precise, stability indicating reversed-phase HPLC method was developed and validated in accordance with ICH guidelines and was s
APA, Harvard, Vancouver, ISO, and other styles
4

Liegeon, Geoffroy. "Impact sur la fonction rénale du ténofovir disoproxil utilisé en prévention des infections par le VIH ou par le virus de l'hépatite B." Thesis, université Paris-Saclay, 2022. http://www.theses.fr/2022UPASR019.

Full text
Abstract:
De nombreuses études montrent que l'utilisation du ténofovir disoproxil (TDF) à titre prophylactique permet de réduire très significativement le nombre de nouvelles contaminations par le VIH et par le virus de l'hépatite B. Cependant, le risque de survenue d'évènements indésirables rénaux sévères peut ralentir la mise en œuvre de ces nouvelles stratégies de prévention. Ce travail de thèse s'est donné pour objectif d'évaluer l'impact rénal du TDF utilisé dans le cadre de la prophylaxie pré-exposition (PrEP) du VIH et dans la prévention de la transmission mère-enfant (PTME) du VHB afin d'élabore
APA, Harvard, Vancouver, ISO, and other styles
5

Tenghe, Lovette Asobo. "Formulation and evaluation of polymeric micelles for improved oral delivery of tenofovir disoproxil fumarate and zidovudine using poly-lactic-co-glycolic acid nanoparticles." University of the Western Cape, 2018. http://hdl.handle.net/11394/6770.

Full text
Abstract:
Magister Pharmaceuticae - MPharm<br>Background: Tenofovir disoproxil fumarate (TDF) and Zidovudine (AZT) are both nucleotide and nucleoside analogue reverse transcriptase inhibitors (NtRTIs and NRTIs), respectively. They are used for the management and prevention of the Human Immunodeficiency Virus (HIV) infection. These drugs are faced with oral delivery challenges such as low intestinal permeability and extensive first pass liver metabolism for TDF and AZT, respectively. Their use may also be limited by dose-dependent adverse effects, which may result in treatment failure when patients becom
APA, Harvard, Vancouver, ISO, and other styles
6

Suleiman, Reem Abdallah S. "Post-market assessment of the quality of first line regimen fixed-dose combination antiretrovirals in South Africa." Thesis, University of the Western Cape, 2017. http://hdl.handle.net/11394/6183.

Full text
Abstract:
Magister Scientiae - MSc (Pharmaceutical Chemistry)<br>The rapid increase in access to new antiretrovirals (ARVs) worldwide and, especially in sub-Saharan Africa, coupled with the well-documented problem of poor quality ARVs in developing countries has underscored the need for quality assessment of these medicines. South Africa has the worst human immunodeficiency virus (HIV) epidemic profile in the world; consequently, it has rolled out the world's largest antiretroviral ARV programme. With increasing market penetration of generic medicine in South Africa and especially ARVs, there is a call
APA, Harvard, Vancouver, ISO, and other styles
7

Simões, Ana Maria Torres 1976. "Estudo dos efeitos da terapêutica antirretroviral na função renal e sua relação no desenvolvimento de insuficiência renal em doentes com infecção por vírus da imunodeficiência humana." Master's thesis, 2017. http://hdl.handle.net/10451/33961.

Full text
Abstract:
Tese de mestrado, Doenças Infecciosas Emergentes, Universidade de Lisboa, Faculdade de Medicina, 2017<br>A introdução na prática clínica de fármacos antivirais cada vez mais potentes e eficazes, como sucede no tratamento da infecção por vírus da imunodeficiência humana, tem conduzido ao aumento da incidência de nefrotoxicidade relacionada com estes fármacos. Material e métodos: No presente estudo retrospectivo foram analisados os processos clínicos de indivíduos adultos com infecção crónica por VIH-1 e seguidos em consulta no Serviço de Doenças Infecciosas do Hospital de Santa Maria, entre 198
APA, Harvard, Vancouver, ISO, and other styles
8

Cautela, Mafalda Pereira. "Vaginal tenofovir disoproxil fumarate - emtricitabine-loaded nanoparticles in films as alternative to oral PrEP." Master's thesis, 2017. http://hdl.handle.net/1822/55584.

Full text
Abstract:
Dissertação de mestrado em Bioquímica Aplicada<br>The human immunodeficiency virus (HIV) infects millions of people every year. Among those, women account for half of these numbers and heterosexual transmission is the predominant mean of infection. Unfortunately, no cure is available, thus making prevention a cornerstone in the battle against HIV. Oral pre-exposure prophylaxis (PrEP) with daily Truvada® (tenofovir disoproxil fumarate/emtricitabine) has been recently approved in various countries but its efficacy in women is less than optimal, namely due to biological and adherence issues.
APA, Harvard, Vancouver, ISO, and other styles
9

Lalinská, Anežka. "Studium interakcí antiretroviálního léčiva tenofoviru a jeho proléčiva tenofoviru disoproxil fumarátu s placentárními nukleosidovými transportéry." Master's thesis, 2018. http://www.nusl.cz/ntk/nusl-382786.

Full text
Abstract:
Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmacology & Toxicology Student: Anežka Lalinská Supervisor: PharmDr. Lukáš Červený, Ph.D. Title of diploma thesis: Study of interactions of antiretroviral drug tenofovir and its prodrug tenofovir disoproxil fumarate with placental nucleoside transporters Tenofovir (TFV) in the form of ester prodrug tenofovir disoproxil fumarate (TDF) is an essential part of combination antiretroviral therapy. It is often used in the prevention of perinatal HIV transmission. However, precise mechanism(s) involved in transfer of TFV/TDF fr
APA, Harvard, Vancouver, ISO, and other styles
10

Bogas, Sarah Brito. "Desenvolvimento de nanofibras poliméricas microbicidas anti-VIH pela técnica de electrospinning." Master's thesis, 2019. http://hdl.handle.net/1822/65256.

Full text
Abstract:
Dissertação de mestrado em Biofísica e Bionanossistemas<br>A infeção pelo vírus da imunodeficiência humana (VIH) provoca uma desregulação no sistema imunológico levando ao aparecimento de várias doenças oportunistas. Recorrendo a fármacos antirretrovirais, que inibem o processo de replicação do vírus, a infeção pode ser controlada e, deste modo, o paciente infetado pode não atingir a última fase da infeção pelo VIH, a Síndrome da Imunodeficiência Adquirida (SIDA). Também se pode recorrer a estes fármacos antirretrovirais para fazer uma profilaxia pré-exposição (PrEP) e assim prevenir a tr
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Tenofovir Disoproxil Fumarate (TDF)"

1

Bell, Tanvir K. Musculoskeletal Complications of HIV. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0043.

Full text
Abstract:
Vitamin D levels have been observed to be low in HIV-infected patients. If replacement of low vitamin D is warranted, supplementation is done with vitamin D2 or D3. HIV-infected patients may be at higher risk for osteopenia, osteoporosis, and fragility fractures. Tenofovir alafenamide has been shown to produce less bone loss compared to tenofovir disoproxil fumarate. Muscle disorders can be debilitating in HIV-infected patients. Myopathies can have a range of presentation from myalgias to rhabdomyolysis. HIV myopathy is a rare proximal muscle disorder that can occur in HIV-infected patients. A
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Tenofovir Disoproxil Fumarate (TDF)"

1

De Clercq, Erik. "Discovery and Development of Tenofovir Disoproxil Fumarate." In Antiviral Drugs. John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9780470929353.ch7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wong, Lena. "Prevention of HIV." In 50 Studies Every Global Health Provider Should Know, edited by Andrea Walker, Anup Agarwal, and Yogesh Jain. Oxford University PressNew York, 2023. http://dx.doi.org/10.1093/med/9780197548721.003.0020.

Full text
Abstract:
Abstract PrEP (pre-exposure prophylaxis) is the prevention of choice for people at “substantial risk” of HIV infection. This trial not only randomized serodiscordant heterosexual couples to pre-exposure prophylaxis, but also gave all participants HIV-1 testing with counseling, risk-reduction counseling, screening and treatment for sexually transmitted infections, free condoms, and referral for male circumcision and post-exposure prophylaxis according to national policies. This trial found an overall relative reduction in HIV acquisition of 67% with tenofovir disoproxil fumarate (TDF) alone and
APA, Harvard, Vancouver, ISO, and other styles
3

Umutesi, Justine, Janvier Serumondo, and Claude Mambo Muvunyi. "Pitfalls in HBV Treatment and Management." In Hepatitis B Virus - Pathogenesis and Therapeutic Approaches [Working Title]. IntechOpen, 2024. https://doi.org/10.5772/intechopen.1005795.

Full text
Abstract:
Although new infections due to viral hepatitis are declining as a result of numerous efforts to prevent and control hepatitis B virus (HBV), it remains the second leading infectious cause of death after tuberculosis. The lack of contextual management of HBV and its consequences may be one of the many reasons for these deaths. Drugs such as tenofovir disoproxil fumarate (TDF) are effective but have serious side effects, including bone and kidney dysfunction, which make survival more uncertain. Tenofovir alafenamide (TAF) has proved safer, more tolerant and more stable in plasma than TDF, but it
APA, Harvard, Vancouver, ISO, and other styles
4

"Tenofovir disoproxil fumarate." In PharmacotherapyFirst Drug Information. The American Pharmacists Association, 2017. http://dx.doi.org/10.21019/druginformation.tenofovir_disoproxil_fumarate.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Tenofovir Disoproxil Fumarate." In Hale’s Medications & Mothers’ Milk™ 2019. Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0986.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"VIREAD (Tenofovir Disoproxil Fumarate)." In Antibiotics Manual. John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119220787.ch194.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Emtricitabine/tenofovir disoproxil fumarate." In PharmacotherapyFirst Drug Information. The American Pharmacists Association, 2017. http://dx.doi.org/10.21019/druginformation.emtricitabine_tenofovir_disoproxil_fumarate.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gurram, Pooja R., and Alan J. Wright. "HIV and Its Myriad Opportunistic Infections." In Mayo Clinic Infectious Disease Case Review, edited by Larry M. Baddour, John C. O’Horo, Mark J. Enzler, and Rahul Kashyap. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780190052973.003.0050.

Full text
Abstract:
Opportunistic infections and coinfections of HIV/AIDS include Pneumocystis pneumonia, hepatitis B virus (HBV), and disseminated Mycobacterium avium complex (MAC). Symptoms of Pneumocystis pneumonia are progressive shortness of breath, dry cough, fever, and chest discomfort. First-line medication for treating Pneumocystis pneumonia is trimethoprim-sulfamethoxazole. For patients with HIV-HBV coinfection, a combination of either lamivudine or emtricitabine plus either tenofovir alafenamide or tenofovir disoproxil fumarate must be used as the nucleoside reverse-transcriptase inhibitor combination.
APA, Harvard, Vancouver, ISO, and other styles
9

Ajmal, Saira R., and Mary J. Kasten. "HIV Prevention." In Mayo Clinic Infectious Disease Case Review, edited by Larry M. Baddour, John C. O’Horo, Mark J. Enzler, and Rahul Kashyap. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780190052973.003.0033.

Full text
Abstract:
Preexposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate/emtricitabine can reduce the risk of HIV infection by more than 90% for patients who are highly adherent. When considering PrEP, the first step is to determine the risk of HIV acquisition based on sexual risk behaviors during the past 6 months. Evaluation should include baseline HIV test, renal function estimate, and hepatitis B screen. Follow-up should be scheduled at 1 month and every 3 months thereafter. The need to continue PrEP should be reassessed on an annual basis, and PrEP should be continued for 1 month after the
APA, Harvard, Vancouver, ISO, and other styles
10

Purnima, B. Valli, G. Ramu, and D. Ramachandran. "First and Second Order Derivative Spectrophotometric Methods for Simultaneous Determination of Emtricitabine and Tenofovir Disoproxil Fumarate Tablets." In Progress in Chemical Science Research Vol. 9. B P International (a part of SCIENCEDOMAIN International), 2023. http://dx.doi.org/10.9734/bpi/pcsr/v9/19277d.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Tenofovir Disoproxil Fumarate (TDF)"

1

Yuen Chan, Henry Lik, Pietro Lampertico, Sang Hoon Ahn, et al. "IDDF2020-ABS-0060 Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF." In Abstracts of the International Digestive Disease Forum (IDDF), 22–23 November 2020, Hong Kong. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2020. http://dx.doi.org/10.1136/gutjnl-2020-iddf.143.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ahn, Sang Hoon, Jia-Horng Kao, Hie-Won Hann, et al. "IDDF2020-ABS-0058 48-week safety and efficacy of switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) in chronic HBV asian patients with TDF risk factors (RF)." In Abstracts of the International Digestive Disease Forum (IDDF), 22–23 November 2020, Hong Kong. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2020. http://dx.doi.org/10.1136/gutjnl-2020-iddf.141.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ahn, Sang Hoon, Jia-Horng Kao, Pietro Lampertico, et al. "IDDF2021-ABS-0080 96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 4–5 September 2021. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2021. http://dx.doi.org/10.1136/gutjnl-2021-iddf.82.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lik Yuen Chan, Henry, Wai Kay Seto, Maria Buti, et al. "IDDF2019-ABS-0168 Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF)." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.277.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yuen Chan, Henry Lik, Young-Suk Lim, Wai Kay Seto, et al. "IDDF2020-ABS-0061 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)." In Abstracts of the International Digestive Disease Forum (IDDF), 22–23 November 2020, Hong Kong. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2020. http://dx.doi.org/10.1136/gutjnl-2020-iddf.144.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chan, Henry Lik-Yuen, Maria Buti, Robert Flisiak, et al. "IDDF2018-ABS-0107 Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF)." In International Digestive Disease Forum (IDDF) 2018, Hong Kong, 9–10 June 2018. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-iddfabstracts.208.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lik Yuen Chan, Henry, Pietro Lampertico, Maria Buti, et al. "IDDF2019-ABS-0169 A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.278.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chan, Henry Lik-Yuen, Wai Kay Seto, Scott Fung, et al. "IDDF2018-ABS-0106 Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies." In International Digestive Disease Forum (IDDF) 2018, Best Abstracts, Hong Kong, 9–10 June 2018. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-iddfbestabstracts.19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lim, Young-Suk, Grace Wong, Sang Hoon Ahn, et al. "IDDF2024-ABS-0205 Impact of long-term treatment with continuous tenofovir alafenamide (TAF) or after switch from tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 10 – 11 August 2024. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2024. http://dx.doi.org/10.1136/gutjnl-2024-iddf.189.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chan, Henry Lek-Yuen, Calvin Pan, Maurizia Brunetto, et al. "IDDF2018-ABS-0108 Improved bone and renal safety at 1 year after switching from TENOFOVIR DISOPROXIL FUMARATE (TDF) to TENOFOVIR ALAFENAMIDE (TAF): results from 2 phase 3 studies in HBEAG-positive and HBEAG-negative patients with chronic hepatitis B (CHB)." In International Digestive Disease Forum (IDDF) 2018, Hong Kong, 9–10 June 2018. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-iddfabstracts.209.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Tenofovir Disoproxil Fumarate (TDF)"

1

Zhang, JunLI, HongYuan Mou, Ying He, and XiaoYu Hu. Fuzheng Huayu Combined with Tenofovir Disoproxil Fumarate for Hepatitis B: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.11.0002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yang, Si-jie, Xin Li, Shi Dong, Zhi-long Shi, Hui Zhang, and Wen-ce Zhou. The Safety and Efficacy of Entecavir Associated with Adefovir Dipivoxil Versus Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B Patient with Adefovir-resistant: a protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.1.0006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Tenofovir Disoproxil Fumarate (TDF)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography